Clinicopathological Characteristics of Colon Cancer in Young Age
1 other identifier
observational
1,400
1 country
1
Brief Summary
A Study on the Characteristics of Colorectal Cancer by Age and sex.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2019
CompletedFirst Submitted
Initial submission to the registry
April 24, 2022
CompletedFirst Posted
Study publicly available on registry
May 9, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
April 28, 2026
April 1, 2026
7.8 years
April 24, 2022
April 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival (overall/disease-specific) according to sex, molecular profiles and sex hormone receptors
Time from diagnosis to death
From date of enrollment until the date of death from colorectal cancer or from any cause, assessed up to 120 months
Secondary Outcomes (1)
Disease-free survival according to sex, molecular profiles and sex hormone receptors
From date of enrollment until the date of first documented recurrence of colorectal cancer, assessed up to 120 months
Study Arms (1)
Colorectal cancer group
Patients treated after being diagnosed with colorectal cancer
Eligibility Criteria
Patients treated after being diagnosed with colorectal cancer, and agreed to participate
You may qualify if:
- Patients treated after being diagnosed with colorectal cancer
You may not qualify if:
- Patients under age of 18 years, or patients who cannot choose whether to participate or not
- Patients who refuse to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 463-707, South Korea
Biospecimen
Microinstability (MSS, MSI-L, MSI-H), DNA mismatch repair genes (hMLH1, hMSH2, hMSH6, hPMS2), RAS genes (KRAS, NRAS, HRAS), BRAF mutations from cancer tissue will be analyzed using immunohistochemistry (IHC) and reverse transcriptase polymerase chain reaction (RT-PCR). In addition, the expression of estrogen and androgen receptors will further be analyzed in each patient.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Nayoung Kim, MD, PhD
Seoul National University Bundang Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 24, 2022
First Posted
May 9, 2022
Study Start
January 1, 2019
Primary Completion (Estimated)
October 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
April 28, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share